Uncategorized

Parabilis reveals IPO plans the day after Regeneron deal as listings heat up

Published

3 weeks ago

on

Parabilis Medicines, the decade-old and well-funded “undruggable” biotech out of Greg Verdine’s Harvard lab, seeks to become the 12th drug developer to conduct an initial public offering this year.

The biotech

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version